News Releases Keyword Search Year None20232022202120202019201820172016 Sep-07-2023 Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board Aug-10-2023 Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results Aug-03-2023 Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results Aug-03-2023 Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer Jun-30-2023 Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Jun-06-2023 Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma May-31-2023 Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference May-04-2023 Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results Apr-27-2023 Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results Apr-13-2023 Oncternal Therapeutics Participating in Oppenheimer & Co.’s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »